Domain Invest

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg
Showing posts with label NEJM. Show all posts
Showing posts with label NEJM. Show all posts

Wednesday, 30 January 2008

Who's Sorry Now? Not Feeling So Good Edition

Posted on 09:50 by Unknown
Nature reports today that a peer reviewer for the New England Journal of Medicine leaked to GlaxoSmithKline that big old Avandia meta-analysis that has been the bane of their existence since it was released in May 2006. (Our coverage of the Avandia debacle can be found here.)

University of Texas Health Science Center professor of epidemiology Steven Haffner, MD, explained to Nature: "Why I sent it is a mystery. I don't really understand it. I wasn't feeling well. It was bad judgement."

Brian Vastag writes in Nature that Haffner faxed the article 17 days ahead of publication to GSK's Alexander Cobitz, whom he had worked with on an earlier trial of Avandia. What happens from there is unclear--though it's not like GSK effectively got out in front of the news, the 17-days head start may have helped them provide a relatively prompt interim analysis of its RECORD study, which was published in the NEJM in June to try to stop the bleeding.

We will likely have more on this later, once the dust settles. For now, we bring you another edition of "Who's Sorry Now?"
  • Steven Haffner to NEJM: Sorry I leaked the Avandia study, but i had a serious cold that day.

  • Senator Grassley's office to Nature: Sorry we broke your embargo on the Avandia news today, but we aren't feeling so hot today ourselves.

  • American Heart Association and American College of Cardiology to patients: sorry we forgot to disclose our potential financial ties to Merck and Schering-Plough, but there's a wicked flu going around the office.

  • Phillies to Mets: Sorry you're spending all that money on Santana, but you're still not winning the NL East this year. Cough.
Read More
Posted in Avandia, NEJM, Vytorin | No comments

Thursday, 16 August 2007

Avandia and Rezulin Redux

Posted on 09:35 by Unknown
We told you about the dangerous parallels between GlaxoSmithKline's diabetes drug Avandia and Warner-Lambert's now-dead TZD Rezulin.

The New England Journal of Medicine has published a piece on making the same connection by Jerry Avorn, a Harvard Medical School professor. I think this quote from Avorn says it all on how he feels about FDA's advisory committee vote (almost unanimous) July 30 to keep Avandia on the market:
"The decision was more suggestive of Rezulin redux (and of Redux) than it was of resolve."
You all remember Redux don't you? To read the whole Avorn piece, click here. As always, your comments are welcome.
Read More
Posted in Avandia, drug safety, NEJM | No comments
Older Posts Home
Subscribe to: Posts (Atom)

Popular Posts

  • While You Were Going to California
    Before the eyes of the healthcare world turn to the overcrowded hallways of the Westin St. Francis, here's a quick roundup of the weeken...
  • More Insulin Problems
    Pfizer isn't the only company having problems with an alternative delivery form of insulin . Emisphere Technologies has been working on ...
  • Unusual Suspects: If Pfizer Decides to Really Rattle the R&D Cages
    Yesterday, we listed a group of people -- we called them the usual suspects -- that we think Pfizer will try to woo if it ends up turning to...
  • Merck: Embracing Externalization, From the Top Down
    Updated Below . One business magazine greeted the tenure of Dick Clark as Merck's new CEO in 2005 with the instruction to "say hel...
  • Ventana Accepts $3.4 Billion
    Roche finally nabs its man. Or in this case, its diagnostics company. All it took was an extra $14.50 per share. From the companies' pre...
  • Buyer’s Remorse: No Love for Medicare Part D on the Campaign Trail
    So Many Happy Faces! None are Running for President in 2008 The Medicare prescription drug benefit known as Part D has been an unmitigated ...
  • M&A: Gulf War
    So there's now a class-action lawsuit that asserts MedImmune's shareholders are getting a raw deal in that company's acquisitio...
  • The Import of FDA to Biotechs, CEO Entourages and a Few More BIO Thoughts
    I just wanted to post a few more impressions I had from the BIO annual meeting in Boston. One thing that struck me in particular is how litt...
  • Sorry, I Still Don’t Get It
    Pfizer launched its first TV campaign for Exubera this past week in an attempt to breathe a little life into the stalled inhaled insulin br...
  • Talking of Sons-of-Drugs…
    Just when we thought that drug companies had given up on some of their more blatant life-cycle management tricks, snubbed by stingy payors w...

Categories

  • Abbott
  • activist shareholders
  • ADHD
  • advisory committees
  • alliances
  • Alnylam
  • Alzheimer's disease
  • Amgen
  • Andrew von Eschenbach
  • Andrew Witty
  • Astellas
  • AstraZeneca
  • Avandia
  • Avastin
  • Barack Obama
  • Barr
  • Bayer
  • Big Pharma
  • BIO
  • Biogen Idec
  • biologics
  • biosimilars
  • blogging
  • BMS
  • Boston Scientific
  • brand names
  • business development
  • business models
  • cancer vaccines
  • Carl Icahn
  • CBO
  • CDER
  • Celgene
  • Cephalon
  • China
  • clinical development
  • CMS
  • co-promotes
  • comparative effectiveness
  • conference
  • Congress
  • consumer genomics
  • corporate culture
  • corporate governance
  • corporate venture capital
  • CVS Caremark
  • Cytyc
  • David Kessler
  • deals of the week
  • debt financing
  • Diabetes
  • diagnostics
  • Dick Clark
  • drug approvals
  • drug delivery
  • drug discovery
  • drug eluting stents
  • Drug Pricing
  • drug safety
  • drug samples
  • DTC Advertising
  • e-health
  • Eisai
  • Elan
  • Eli Lilly
  • Emphasys
  • emphysema
  • Endo
  • epo
  • Euro-Biotech Forum
  • Exits
  • Exubera
  • FDA
  • FDA/CMS Summit
  • FDAAA
  • Film and TV
  • financing
  • FOBs
  • Forest Labs
  • Galvus
  • gene therapy
  • Genentech
  • General Electric
  • generics
  • Genzyme
  • Gleevec
  • Google
  • GSK
  • Guidant
  • haircuts
  • Happy Holidays
  • HCV
  • Headhunting
  • Health Care Reform
  • hedge funds
  • Henry Waxman
  • hGH
  • HHS
  • Hillary Clinton
  • Hologic
  • hostile takeovers
  • hypertension
  • ImClone
  • IMS Health
  • In vitro diagnostics
  • In3
  • India
  • insomnia
  • instrumentation
  • insulin
  • Inverness
  • IP
  • IPO
  • IPO pricing
  • Isis Pharmaceuticals
  • Israel
  • IT
  • JAMA
  • Januvia
  • Japan
  • John McCain
  • Johnson and Johnson
  • JP Morgan
  • LaMattina
  • lawsuits
  • layoffs
  • legislation
  • Life-Cycle Management
  • Lipitor
  • Lucentis
  • management succession
  • Mark McClellan
  • marketing
  • Martin Mackay
  • medical devices
  • Medicare
  • Medicare Part D
  • Medimmune
  • Medtech Insight
  • Medtronic
  • Merck
  • Merck-Serono
  • mergers and acquisitions
  • Michael McCaughan
  • Millennium
  • mmm beer
  • MRI
  • multiple sclerosis
  • music
  • nanotechnology
  • NEJM
  • new drug approvals
  • new funds
  • NICE
  • NicOx
  • NIH
  • Nobel Prize
  • Novartis
  • Novo Nordisk
  • Nycomed
  • off-label promotion
  • oncology
  • ophthalmology
  • Orthopedics
  • osteoporosis
  • OTC drugs
  • Out-Partnering
  • Oxycontin
  • pain
  • Part D
  • Patient Advocacy
  • PDUFA
  • personalized medicine
  • Pfizer
  • pharmacy benefits
  • PhRMA
  • politics
  • poll results
  • PR
  • prasugrel
  • Presidential Election
  • Press Release of the Week
  • Primary Care
  • private equity
  • Procter and Gamble
  • PSA
  • Purdue Pharma
  • rare diseases
  • reimbursement
  • research and development productivity
  • research and development strategies
  • reverse mergers
  • rimonabant
  • RiskMAP
  • RNAi
  • Roche
  • Roger Longman
  • royalties
  • sales forces
  • Sanofi-aventis
  • Schering-Plough
  • Science Matters
  • Sepracor
  • shameless self-promotion
  • share buybacks
  • Shire
  • Sirtris
  • Smith and Nephew
  • Solvay
  • SPACs
  • spec pharma
  • spin-outs
  • sports
  • Start-Up
  • statins
  • Steve Nissen
  • Stryker
  • Supreme Court
  • Takeda
  • Teva
  • Thanksgiving
  • The RPM Report
  • UCB
  • vaccines
  • Velcade
  • Ventana
  • venture capital
  • venture debt
  • Venture Round
  • Vertex
  • Vioxx
  • Vytorin
  • Wacky World of Generics
  • While You Were ...
  • Wyeth
  • Zetia
  • Zimmer
  • ZymoGenetics

Blog Archive

  • ▼  2008 (76)
    • ▼  February (25)
      • The Wacky World of Generics: Risperdal Edition
      • Botox, Friday Afternoon Press Calls and the Nissen...
      • AZ Makes Its Move in GI
      • Nektar Takes A Deep Breath
      • Sanofi Aventis: Sign of the Big Pharma Times?
      • The Blockbuster Model is Dead, Sort Of
      • Starring Role for Follow-On Biologics
      • While You Were Settling
      • Reputation Counts
      • Friday Night Lowlights: Don't Leave Town Early
      • FDA-CMS Parallel Reviews: A Mixed Bag
      • Deals of the Week: Winter of Our Discontent
      • Beijing Boost for Japanese Encephalitis Vaccine
      • Carl Icahn vs. Evil Corporate Governance
      • FDA’s Search for a Drug Chief Not Going Well: An I...
      • The Wacky World of Generics: Fosamax Edition
      • FDA’s Budget: “Maintain Momentum” or “Inadequate R...
      • White House Tries to Jump-Start Follow-On Biologics
      • Why Big Pharma Should Vote Democratic
      • The Wacky World of Generics: Protonix Edition
      • Perlmutter: We're Not Abandoning Japan
      • Amgen Cashes out of Japan; Follows Bristol's Risk ...
      • While You Were Eating Chili and Drinking Beer
      • Cervarix: Big Step for FDA; Can GSK Make the Decis...
      • Deals of the Week: Deal--or No Deal
    • ►  January (51)
  • ►  2007 (329)
    • ►  December (32)
    • ►  November (42)
    • ►  October (37)
    • ►  September (33)
    • ►  August (29)
    • ►  July (39)
    • ►  June (39)
    • ►  May (43)
    • ►  April (16)
    • ►  March (13)
    • ►  February (5)
    • ►  January (1)
  • ►  2006 (8)
    • ►  December (3)
    • ►  November (5)
Powered by Blogger.

About Me

Unknown
View my complete profile